1-4 of 4
Helen Heyerdahl
Close
Sort by
Journal Articles

NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies

Roman Generalov, Elisa Fiorito, Stian Foss, Veronique Pascal, Helen Heyerdahl, Ada Repetto-Llamazares, Jan Terje Andersen, Geir E Tjønnfjord, Sigrid Strand Skånland, Jostein Dahle
Journal: Blood
Blood (2022) 140 (Supplement 1): 3123–3124.
https://doi.org/10.1182/blood-2022-166275
Published: 2022
Journal Articles

B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life

Elisa Fiorito, Roman Generalov, Stian Foss, Helen Heyerdahl, Ada Repetto-Llamazares, Veronique Pascal, Geir E Tjønnfjord, Sigrid Strand Skånland, Jan Terje Andersen, Jostein Dahle
Journal: Blood
Blood (2022) 140 (Supplement 1): 6012–6013.
https://doi.org/10.1182/blood-2022-159382
Published: 2022
Journal Articles

The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

Tara Helen Dowling Dowling Steinsland, MSc, Stein-Erik Gullaksen, MS, PhD, Geir Bredholt, PhD, Calum Leitch, PhD, Mireia Mayoral Safont, BS, Øystein Bruserud, MD PhD, Mihaela Popa, Astri Maaland, Helen Heyerdahl, PhD, Jostein Dahle, PhD, Bjorn T. Gjertsen, MD PhD, Emmet Mccormack, BSc, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26.
https://doi.org/10.1182/blood-2020-142899
Published: 2020
Journal Articles

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Amal Saidi, PhD, Astri Maaland, Julien Torgue, PhD, Helen Heyerdahl, PhD, Jostein Dahle, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4422.
https://doi.org/10.1182/blood-2018-99-110297
Published: 2018